Related Experiment Video
Updated: Mar 29, 2026
09:20
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
9.1K
Ciliopathies: Does HDAC6 Represent a New Therapeutic Target?
1State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China.
Trends in Pharmacological Sciences
|December 15, 2015
Summary
Histone deacetylase 6 (HDAC6) drives ciliary disassembly in ciliopathies. Inhibiting HDAC6 shows potential for restoring ciliary function and treating these complex genetic disorders.
Area of Science:
- Cell Biology
- Genetics
- Biochemistry
Background:
- Cilia are vital cellular structures involved in signaling and fluid flow.
- Defects in cilia cause human diseases called ciliopathies.
- Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme with known regulatory roles.
Purpose of the Study:
- To investigate the role of HDAC6 in ciliary disassembly.
- To explore the therapeutic potential of HDAC6 inhibitors for ciliopathies.
Main Methods:
- Review of recent findings on HDAC6 function.
- Analysis of HDAC6's role in mediating ciliary disassembly.
- Evaluation of HDAC6 inhibitors in ciliopathy models.
Main Results:
- HDAC6 is identified as a key mediator of ciliary disassembly.
- Small-molecule HDAC6 inhibitors have restored ciliary structure and function.
- HDAC6 activity is crucial for maintaining ciliary integrity.
Conclusions:
- HDAC6 plays a significant role in ciliary disassembly.
- HDAC6 inhibitors represent a promising therapeutic strategy for ciliopathies.
- Targeting HDAC6 offers a potential treatment avenue for various genetic disorders affecting cilia.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
02:30Histone Variants at the Centromere
5.3K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.3K
00:50Anaphase Promoting Complex
3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
02:34Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
02:15M-Cdk Drives Transition Into Mitosis
6.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K